Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 101–200 of 1,119
Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Cheung, K.-H., Shineman, D., Müller, M., Cárdenas, C., Mei, L., Yang, J., Tomita, T., Iwatsubo, T., Lee, V. M.-Y., & Foskett, J. K. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.015 · Cited by 450
REVIEW: Curcumin and Alzheimer’s disease
Hamaguchi, T., Ono, K., & Yamada, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00147.x · Cited by 450
Bazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441
“Then the oligomer Aβ42 accumulates as an aggregate and becomes a major component of senile plaques (37, 75, 77, 85-87).”
BackgroundCopper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases)
Kozlowski, H., Luczkowski, M., Remelli, M., & Valensin, D. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.013 · Cited by 437
Synapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436
Calvo-Rodriguez, M., Hou, S. S., Snyder, A. C., Kharitonova, E. K., Russ, A. N., Das, S., Fan, Z., Muzikansky, A., Garcia-Alloza, M., Serrano-Pozo, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16074-2 · Cited by 430
Folding versus aggregation: Polypeptide conformations on competing pathways
Jahn, T. R., & Radford, S. E. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.05.015 · Cited by 428
Metastability of Native Proteins and the Phenomenon of Amyloid Formation
Baldwin, A. J., Knowles, T. P. J., Tartaglia, G. G., Fitzpatrick, A. W., Devlin, G. L., Shammas, S. L., Waudby, C. A., Mossuto, M. F., Meehan, S., Gras, S. L., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2017703 · Cited by 426
Protein Folding in the Cytoplasm and the Heat Shock Response
Vabulas, R. M., Raychaudhuri, S., Hayer-Hartl, M., & Hartl, F. U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004390 · Cited by 428
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
“[242,243].”
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
“The latest data now indicate that soluble oligomeric species play a critical role in the pathogenicity of AD (for reviews, see Haass and Selkoe 2007; Walsh and Selkoe 2007).”
BackgroundMolecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
“Recent evidence suggests that this toxicity may be linked to the aggregation state of the peptide, implicating oligomers, rather than insoluble fibrils, as the primary toxic species [5, 6].”
BackgroundA molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers
Cohen, S. I. A., Arosio, P., Presto, J., Kurudenkandy, F. R., Biverstål, H., Dolfe, L., Dunning, C., Yang, X., Frohm, B., Vendruscolo, M., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2971 · Cited by 414
Stabilization of a β-hairpin in monomeric Alzheimer's amyloid-β peptide inhibits amyloid formation
Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S., & Härd, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711731105 · Cited by 410
“[Z C28S] / [Aβ(1-40)] Aβ3 kc al / m ol e of Z A β3”
BackgroundExosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy
Liao, W., Du, Y., Zhang, C., Pan, F., Yao, Y., Zhang, T., & Peng, Q. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.045 · Cited by 411
Human Hsp70 Disaggregase Reverses Parkinson’s-Linked α-Synuclein Amyloid Fibrils
Gao, X., Carroni, M., Nussbaum-Krammer, C., Mogk, A., Nillegoda, N. B., Szlachcic, A., Guilbride, D. L., Saibil, H. R., Mayer, M. P., & Bukau, B. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.012 · Cited by 407
“Disassembled a-Syn Species Are Less Toxic Than Fibrils For many amyloidogenic proteins, including a-Syn, small, soluble prefibrillar oligomers are more toxic to cells than mature fibrils (Haass and Selkoe, 2007).”
Exercise hormone irisin is a critical regulator of cognitive function
Islam, M. R., Valaris, S., Young, M. F., Haley, E. B., Luo, R., Bond, S. F., Mazuera, S., Kitchen, R. R., Caldarone, B. J., Bettio, L. E. B., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00438-z · Cited by 403
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
The two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
“lead to mild cognitive impairment (MCI) at early stages of AD (Haass and Selkoe, 2007).”
BackgroundResultInfluentialSelf-citationStructure of an Intermediate State in Protein Folding and Aggregation
Neudecker, P., Robustelli, P., Cavalli, A., Walsh, P., Lundström, P., Zarrine-Afsar, A., Sharpe, S., Vendruscolo, M., & Kay, L. E. (2012) · Science · doi:10.1126/science.1214203 · Cited by 398
η-Secretase processing of APP inhibits neuronal activity in the hippocampus
Willem, M., Tahirovic, S., Busche, M. A., Ovsepian, S. V., Chafai, M., Kootar, S., Hornburg, D., Evans, L. D. B., Moore, S., Daria, A., et al. (2015) · Nature · doi:10.1038/nature14864 · Cited by 398
Self-citationHamaguchi, T., Ono, K., Murase, A., & Yamada, M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090417 · Cited by 398
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
“There was less reduction in plasma Aβ1-40 and Aβ1-42 in the 20 patients with AD and mild cognitive impairment (MCI) compared with 10 control patients (Watson et al., 2005).”
BackgroundAmyloid-like Self-Assembly of a Cellular Compartment
Boke, E., Ruer, M., Wühr, M., Coughlin, M., Lemaitre, R., Gygi, S. P., Alberti, S., Drechsel, D., Hyman, A. A., & Mitchison, T. J. (2016) · Cell · doi:10.1016/j.cell.2016.06.051 · Cited by 393
“…proteins have largely been studied in the context of neurodegenerative diseases, such as Alzheimer’s Cell 166, 637–650, July 28, 2016 ª 2016 Elsevier Inc. 637 95°C disease, amyotrophic lateral sclerosis, or prion diseases (Haass and Selkoe, 2007; Koo et al., 1999; Polymenidou and Cleveland, 2011).”
Calcium hypothesis of Alzheimer’s disease
Berridge, M. J. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0736-1 · Cited by 383
“that the peptides themselves have a more important role to play in disease progression [17, 30].”
BackgroundCalpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration
Vosler, P. S., Brennan, C. S., & Chen, J. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8036-x · Cited by 382
Preventing Alzheimer’s Disease
Selkoe, D. J. (2012) · Science · doi:10.1126/science.1228541 · Cited by 376
Self-citationAmyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
Protein homeostasis and aging in neurodegeneration
Douglas, P. M., & Dillin, A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201005144 · Cited by 372
“Refocused efforts have demonstrated that soluble, oligomeric intermediates in the A aggregation pathway are the most toxic entity (Haass and Selkoe, 2007; Shankar et al., 2008).”
Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease
Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372
“Over the past two to three decades significant progress has been made in understanding the genetics, biology and pathology of AD [11, 44, 65, 148].”
Chen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368
Bleiholder, C., Dupuis, N. F., Wyttenbach, T., & Bowers, M. T. (2011) · Nature Chemistry · doi:10.1038/nchem.945 · Cited by 366
Misfolded proteins in Alzheimer's disease and type II diabetes
DeToma, A. S., Salamekh, S., Ramamoorthy, A., & Lim, M. H. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15112f · Cited by 361
A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers
Thibaudeau, T. A., Anderson, R. T., & Smith, D. M. (2018) · Nature Communications · doi:10.1038/s41467-018-03509-0 · Cited by 360
The amyloid hypothesis on trial
Makin, S. (2018) · Nature · doi:10.1038/d41586-018-05719-4 · Cited by 360
Zhang, X., Tian, Y., Li, Z., Tian, X., Sun, H., Liu, H., Moore, A., & Ran, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405239v · Cited by 354
Preparation and Characterization of Neurotoxic Tau Oligomers
Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Jackson, G. R., & Kayed, R. (2010) · Biochemistry · doi:10.1021/bi1016233 · Cited by 359
Protein Misfolding and Neurodegeneration
Soto, C., & Estrada, L. D. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.56 · Cited by 352
“In addition, the concept that protein deposits are static and irreversible structures has been changing in the last several years to accommodate recent results showing that the protein component of aggregates as well as the associated proteins are in dynamic equilibrium with the soluble version of the proteins.(19,20,…”
BackgroundResultInfluentialTREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury
Mazaheri, F., Snaidero, N., Kleinberger, G., Madore, C., Daria, A., Werner, G., Krasemann, S., Capell, A., Trümbach, D., Wurst, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201743922 · Cited by 351
“Furthermore, for several neurodegenerative diseases, evidence exists that soluble oligomers, which may be rather stable intermediates of the aggregation process of amyloidogenic proteins, are the executers of neurotoxicity [2].”
Self-citationMolecular mechanisms of dendrite stability
Koleske, A. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3486 · Cited by 351
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease
Govindarajan, N., Rao, P., Burkhardt, S., Sananbenesi, F., Schlüter, O. M., Bradke, F., Lu, J., & Fischer, A. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201923 · Cited by 342
“Pathological features of AD are extracellular plaques, comprised of aggregated amyloid-b (A b ) peptides, and intraneuronal tangles that consist of aggregated and hyperphosphorylated tau protein (Haass & Selkoe, 2007; Schneider & Mandelkow, 2008).”
A Practical Review of Proteasome Pharmacology
Thibaudeau, T. A., & Smith, D. M. (2019) · Pharmacological Reviews · doi:10.1124/pr.117.015370 · Cited by 344
The Zyggregator method for predicting protein aggregation propensities
Tartaglia, G. G., & Vendruscolo, M. (2008) · Chemical Society Reviews · doi:10.1039/b706784b · Cited by 349
In Situ Architecture and Cellular Interactions of PolyQ Inclusions
Bäuerlein, F. J. B., Saha, I., Mishra, A., Kalemanov, M., Martínez-Sánchez, A., Klein, R., Dudanova, I., Hipp, M. S., Hartl, F. U., Baumeister, W., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.009 · Cited by 349
“…to toxicity in many of these proteinopathies, whereas the large insoluble inclusions found in the brains of patients and in animal and cellular models are often regarded as oligomer-sequestering protective entities (Arrasate and Finkbeiner, 2012; Bucciantini et al., 2002; Haass and Selkoe, 2007).”
Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer
Kayed, R., Pensalfini, A., Margol, L., Sokolov, Y., Sarsoza, F., Head, E., Hall, J., & Glabe, C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808591200 · Cited by 348
Yang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-16.2016 · Cited by 347
“Immunotherapy with antibodies able to neutralize the toxicity of oligomeric A species is proposed as a chronic therapy for AD (Klyubin et al., 2005; Haass and Selkoe, 2007; Walsh and Selkoe, 2007; Lord et al., 2009; Lannfelt et al., 2014; Sevigny et al., 2016), and therefore it is important for…”
BackgroundSelf-citationmicroRNA-34c is a novel target to treat dementias
Zovoilis, A., Agbemenyah, H. Y., Agis‐Balboa, R. C., Stilling, R. M., Edbauer, D., Rao, P., Farinelli, L., Delalle, I., Schmitt, A., Falkai, P., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.327 · Cited by 353
“The hippocampus is a key brain structure for memory formation and among the first brain regions to be affected during aging and in neurodegenerative dementias such as Alzheimer’s disease (AD), which arises on the pathological background of amyloid b plaques, neurofibrillary tangels, synaptic and neuronal loss (Mesulam…”
BackgroundSalminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.001 · Cited by 346
The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology
Doifode, T., Giridharan, V. V., Generoso, J. S., Bhatti, G., Collodel, A., Schulz, P. E., Forlenza, O. V., & Barichello, T. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105314 · Cited by 347
Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease
Resende, R., Moreira, P. I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C., & Oliveira, C. R. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.012 · Cited by 343
“Although the mechanisms through which Aβ exerts its toxicity remain unclear, it seems that oxidative stress plays an important role [6,7].”
BackgroundMori, K., Lammich, S., Mackenzie, I. R. A., Forné, I., Zilow, S., Kretzschmar, H., Edbauer, D., Janssens, J., Kleinberger, G., Cruts, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1088-7 · Cited by 342
Self-citationTruncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
“These species are thought to be the driving factor for the formation of amyloid plaques and the neurotoxic effects [12].”
BackgroundAmylin deposition in the brain: A second amyloid in Alzheimer disease?
Jackson, K., Barisone, G. A., Diaz, E., Jin, L., DeCarli, C., & Despa, F. (2013) · Annals of Neurology · doi:10.1002/ana.23956 · Cited by 340
“Amylin oligomerization can injure neurons by forming membrane-permeant oligomers,(28,29) similar to the Ab oligomer-induced pathology.(25,27,31,43) Previous results demonstrated that amylin oligomers alter Ca(21) homeostasis and viability of cultured astrocytes(31) and neurons.”
Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity
Fändrich, M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.006 · Cited by 340
Cano, A., Ettcheto, M., Chang, J.-H., Barroso, E., Espina, M., Kühne, B. A., Barenys, M., Auladell, C., Folch, J., Souto, E. B., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.010 · Cited by 337
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Wei, H., Zou, H., Sheikh, A. M., Malik, M., Dobkin, C., Brown, W. T., & Li, X. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-52 · Cited by 333
Park, L., Zhou, P., Pitstick, R., Capone, C., Anrather, J., Norris, E. H., Younkin, L., Younkin, S., Carlson, G., McEwen, B. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711568105 · Cited by 332
“The mechanisms by which A leads to cognitive impairment have not been completely elucidated, although recent evidence suggests that small aggregates of A may be key pathogenic factors by disrupting synaptic function and inducing neuronal death (2).”
BackgroundInfluentialDelekate, A., Füchtemeier, M., Schumacher, T., Ulbrich, C., Foddis, M., & Petzold, G. C. (2014) · Nature Communications · doi:10.1038/ncomms6422 · Cited by 332
Åslund, A., Sigurdson, C. J., Klingstedt, T., Grathwohl, S., Bolmont, T., Dickstein, D. L., Glimsdal, E., Prokop, S., Lindgren, M., Konradsson, P., et al. (2009) · ACS Chemical Biology · doi:10.1021/cb900112v · Cited by 331
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Mosconi, L. (2013) · Clinical and Translational Imaging · doi:10.1007/s40336-013-0026-y · Cited by 328
“Soluble Ab oligomers disrupt longterm potentiation and reduce synaptic plasticity in the hippocampus early in the course of the disease [5].”
BackgroundSalminen, A., Kauppinen, A., Suuronen, T., Kaarniranta, K., & Ojala, J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-41 · Cited by 329
Greene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Liao, Y., Chang, Y., Yoshiike, Y., Chang, Y., & Chen, Y. (2012) · Small · doi:10.1002/smll.201201068 · Cited by 324
A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system
Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21623 · Cited by 322
Niwa, T., Ying, B.-W., Saito, K., Jin, W., Takada, S., Ueda, T., & Taguchi, H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811922106 · Cited by 321
“This is of particular interest because recent advances on amyloid-forming proteins have revealed that soluble oligomeric species of some amyloid proteins are toxic to the cell (29).”
BackgroundNeuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease
Thal, D. R., Walter, J., Saido, T. C., & Fändrich, M. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1375-y · Cited by 319
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action
Karagöz, G. E., Duarte, A. M. S., Akoury, E., Ippel, H., Biernat, J., Morán Luengo, T., Radli, M., Didenko, T., Nordhues, B. A., Veprintsev, D. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.037 · Cited by 318
“The Hsp90-Tau Interaction and Therapeutic Treatment of Alzheimer Disease Aggregation of the Tau microtubule binding region causes Alzheimer disease (Haass and Selkoe, 2007; Kosik et al., 1986).”
BackgroundMitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation
Leuner, K., Schütt, T., Kurz, C., Eckert, S. H., Schiller, C., Occhipinti, A., Mai, S., Jendrach, M., Eckert, G. P., Kruse, S. E., et al. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4173 · Cited by 354
Self-citationAdolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
“Inhibition of A assembly and disaggregation of preformed protofibrillar A peptides by MABT The binding epitope of MABT was mapped to amino acids 12–23 of A 1– 42, and therefore overlaps with the main hydrophobic cationic segment of A 1– 42 responsible for the self-association, subsequent oligomerization, and the core…”
BackgroundMethodWright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., Clark, I. A., Abdipranoto, A., & Vissel, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059586 · Cited by 313
“Plaques result from the cleavage of the Ab precursor protein (APP) by b- and c-secretases into 39–43 amino acid Ab peptides within the cerebral cortex, hippocampus and amygdala [3,4].”
BackgroundAstrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
“plaque burden does not correlate well with symptomatic disease progression, increases in soluble Ab species do correlate with progression of clinical symptoms (Haass and Selkoe, 2007; Lue et al., 1999; McLean et al., 1999; Näslund et al., 2000).”
BackgroundLipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice
Martins, I. C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Van Gelder, P., Hartmann, D., D'Hooge, R., De Strooper, B., et al. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601953 · Cited by 311
“A number of species have been observed: dimeric and trimeric Aboligomers (Podlisny et al, 1995, 1998; McLean et al, 1999; Walsh et al, 2002a), 56* kDa oligomer assemblies from transgenic mouse brains (Lesne et al, 2006) or larger structures that consist of 50 and more Ab peptides (Lambert et al, 1998; Walsh et al, 199…”
BackgroundHeat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Neef, D. W., Jaeger, A. M., & Thiele, D. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3453 · Cited by 307
Recognition of the amyloid precursor protein by human γ-secretase
Zhou, R., Yang, G., Guo, X., Zhou, Q., Lei, J., & Shi, Y. (2019) · Science · doi:10.1126/science.aaw0930 · Cited by 304
Mechanism of amyloid plaque formation suggests an intracellular basis of Aβ pathogenicity
Friedrich, R. P., Tepper, K., Rönicke, R., Soom, M., Westermann, M., Reymann, K., Kaether, C., & Fändrich, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904532106 · Cited by 303
“Aβ(1–40) and Aβ(1–42) are able to adopt many differently shaped aggregates including amyloid fibrils (8–11) as well as nonfibrillar aggregates that are sometimes termed also Aβ “oligomers” (12, 13).”
BackgroundThe insulin paradox: aging, proteotoxicity and neurodegeneration
Cohen, E., & Dillin, A. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2474 · Cited by 303
Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302
Mitochondrial dynamics in cell death and neurodegeneration
Cho, D.-H., Nakamura, T., & Lipton, S. A. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0435-2 · Cited by 296
“Ab is generated by proteolytic processing of amyloid precursor protein (APP) by b- and c-secretase in the transmembrane region [123, 126].”
BackgroundSey, N. Y. A., Hu, B., Mah, W., Fauni, H., McAfee, J. C., Rajarajan, P., Brennand, K. J., Akbarian, S., & Won, H. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0603-0 · Cited by 297
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Dendritic Spine Loss and Synaptic Alterations in Alzheimer’s Disease
Knobloch, M., & Mansuy, I. M. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8018-z · Cited by 296
“Several studies have now provided evidence that small Aβ assemblies might indeed be the main neurotoxic species in AD (for recent reviews on the role of Aβ oligomers in AD, see [22, 23]).”
BackgroundResveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation
Feng, Y., Wang, X.-P., Yang, S.-G., Wang, Y.-J., Zhang, X., Du, X.-T., Sun, X.-X., Zhao, M., Huang, L., & Liu, R.-T. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.08.013 · Cited by 295
Wan, Y.-W., Al-Ouran, R., Mangleburg, C. G., Perumal, T. M., Lee, T. V., Allison, K., Swarup, V., Funk, C. C., Gaiteri, C., Allen, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107908 · Cited by 323
“…including similar protein aggregate pathologies, proteostatic and oxidative stress, neuroinflammation, and the critical role of aging in disease risk and/or progression (Block and Hong, 2005; Bucciantini et al., 2002; Guo and Lee, 2014; Haass and Selkoe, 2007; Nixon, 2005; Ross and Poirier, 2004).”
BackgroundBartels, T., Ahlstrom, L. S., Leftin, A., Kamp, F., Haass, C., Brown, M. F., & Beyer, K. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.06.035 · Cited by 292
Self-citationInterrogating Amyloid Aggregates using Fluorescent Probes
Aliyan, A., Cook, N. P., & Martí, A. A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00404 · Cited by 290
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
“Aβ42 oligomer concentrations in the range of 1–10 μM induce cell death in primary neuron culture (reviewed in [16]).”
Swaminathan, R., Ravi, V. K., Kumar, S., Kumar, M. V. S., & Chandra, N. (2011) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/b978-0-12-386483-3.00003-3 · Cited by 291
“With the increasing belief that oligomeric form of protein or prefibrillar aggregates is pathogenic in nature, it is imperative to target these species to fight PMDs (Haass and Selkoe, 2007).”
BackgroundInfluentialOlfactory Dysfunction Correlates with Amyloid-β Burden in an Alzheimer's Disease Mouse Model
Wesson, D. W., Levy, E., Nixon, R. A., & Wilson, D. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4622-09.2010 · Cited by 290
“For example, soluble oligomeric forms of A are important in mediating AD-like neurodegeneration (Varvel et al., 2008) and in modulating synaptic activity (Haass and Selkoe, 2007).”
BackgroundInteraction between Human Prion Protein and Amyloid-β (Aβ) Oligomers
Chen, S., Yadav, S. P., & Surewicz, W. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145516 · Cited by 289
Alzheimer’s Disease: An Update and Insights Into Pathophysiology
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.742408 · Cited by 279
Development of tau aggregation inhibitors for alzheimer's disease
Bulic, B., Pickhardt, M., Schmidt, B., Mandelkow, E., Waldmann, H., & Mandelkow, E. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802621 · Cited by 286
Exercise counteracts declining hippocampal function in aging and Alzheimer's disease
Intlekofer, K. A., & Cotman, C. W. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.011 · Cited by 286
“Measurement of these soluble Aβ oligomers may have important implications for AD, as these are considered the primary toxic species because their abundance correlates with the severity of neurodegeneration and synaptic dysfunction in AD (Haass and Selkoe, 2007).”
BackgroundPolyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao, J., & Diamond, M. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm213 · Cited by 287
Computational Modeling of β-Secretase 1 (BACE-1) Inhibitors Using Ligand Based Approaches
Subramanian, G., Ramsundar, B., Pande, V., & Denny, R. A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00290 · Cited by 285
Timing-Dependent Septal Cholinergic Induction of Dynamic Hippocampal Synaptic Plasticity
Gu, Z., & Yakel, J. L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.026 · Cited by 285
“…the soluble oligomeric rather than the fibrillar form of b-amyloid (Ab) causes synaptic and cognitive dysfunction in AD, and the underlyingmechanisms have, therefore, been the focus of current studies (Lue et al., 1999; McLean et al., 1999; Selkoe, 2002; Hsieh et al., 2006; Haass and Selkoe, 2007).”
van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
“Aβ forms upon cleavage of the amyloid precursor protein by β- and γ-secretases, and accumulates extracellularly (1).”
BackgroundEmerging Roles of Extracellular Vesicles in the Nervous System
Rajendran, L., Bali, J., Barr, M. M., Court, F. A., Krämer-Albers, E.-M., Picou, F., Raposo, G., van der Vos, K. E., van Niel, G., Wang, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3258-14.2014 · Cited by 292
“Amyloidogenesis usually refers to the pathological formation of insoluble fibrous aggregates from proteins, such as the APP during AD (Haass and Selkoe, 2007; Greenwald and Riek, 2010).”
Background
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.